Raymond James Financial
INKT icon

Raymond James Financial’s MiNK Therapeutics INKT Stock Holding History

Raymond James Financial’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32
Closed -$236 – 5812
2025
Q2 		$236 Buy
+32
New +$241 ﹤0.01% 6761

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
C
Covestor London, United Kingdom $173M AUM 56.91% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Raymond James Financial's INKT Position: Q3 2025 in Review

Raymond James Financial sold out of MiNK Therapeutics (INKT) in Q3 2025, closing a stake of 32 shares — an estimated $236 sold.

Raymond James Financial first reported a position in INKT in Q2 2025 and held it in 1 quarter. The position peaked at $236 in Q2 2025. 18 funds tracked by Wall St. Rank hold INKT as of Q3 2025.

  • Raymond James Financial reported no remaining MiNK Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 32 MiNK Therapeutics shares in Q3 2025, an estimated $236.
  • Raymond James Financial first reported a position in MiNK Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's MiNK Therapeutics position peaked at $236 in Q2 2025.
  • 18 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.